Anzeige
Mehr »
Donnerstag, 07.08.2025 - Börsentäglich über 12.000 News
Große CEO-Enthüllung: Analysten sehen +56% Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QJEC | ISIN: CA45257F2008 | Ticker-Symbol: TQB
Tradegate
06.08.25 | 20:08
1,590 Euro
-1,24 % -0,020
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
IMMUNOPRECISE ANTIBODIES LTD Chart 1 Jahr
5-Tage-Chart
IMMUNOPRECISE ANTIBODIES LTD 5-Tage-Chart
RealtimeGeldBriefZeit
1,5801,65010:25
1,5801,65010:05

Aktuelle News zur IMMUNOPRECISE ANTIBODIES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiImmunoPrecise Antibodies Ltd. - 6-K, Report of foreign issuer4
MiImmunoPrecise Antibodies divests Netherlands facilities to AVS Bio2
MiImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI Innovation138ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), a biotherapeutics company delivering advanced solutions in biologics and drug discovery, today announced the successful sale of...
► Artikel lesen
IMMUNOPRECISE ANTIBODIES Aktie jetzt für 0€ handeln
MiAVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities With Acquisition of ImmunoPrecise Antibodies Europe From ImmunoPrecise Antibodies Ltd.175Arlington Capital Partners ("Arlington"), a Washington, D.C.-area private investment firm specializing in government regulated industries, today announced that its portfolio company AVS Bio, a leading...
► Artikel lesen
29.07.ImmunoPrecise GAAP EPS of -$0.05 misses by $0.01, revenue of $6.98M beats by $1.47M7
29.07.ImmunoPrecise Antibodies Ltd. - 6-K, Report of foreign issuer2
29.07.ImmunoPrecise Antibodies Ltd. - 20-F, Annual and transition report of foreign private issuers5
21.07.ImmunoPrecise Antibodies Ltd. - 6-K, Report of foreign issuer2
14.07.ImmunoPrecise Antibodies Ltd. - 6-K, Report of foreign issuer13
14.07.ImmunoPrecise regains Nasdaq compliance on minimum bid price6
14.07.ImmunoPrecise regains Nasdaq compliance as share price stabilizes7
03.07.ImmunoPrecise Antibodies Ltd. - 6-K, Report of foreign issuer26
24.06.ImmunoPrecise Antibodies Ltd. - 6-K, Report of foreign issuer10
13.06.ImmunoPrecise stock rating reiterated at Buy by H.C. Wainwright11
12.06.ImmunoPrecise Antibodies Ltd. - 6-K, Report of foreign issuer12
05.06.ImmunoPrecise Antibodies Ltd. - 6-K, Report of foreign issuer6
21.05.ImmunoPrecise Antibodies Ltd. - 6-K, Report of foreign issuer5
12.05.ImmunoPrecise Antibodies Ltd. - 6-K, Report of foreign issuer7
14.04.H.C. Wainwright sets $50 target for ImmunoPrecise stock16
10.04.ImmunoPrecise Antibodies Ltd. - 6-K, Report of foreign issuer2
Weiter >>
38 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1